Helloworld trades at $1.79 vs $5.06 fair value (183% upside). FY26 revenue $238.6m (+23.8%) driven by MTA acquisition. EBITDA margins 32.5% peak. Risk-adjusted return 174% with 86/100 confidence. Key risks: MTA integration, digital disruption, economic sensitivity.
View noteReece trades at $14.93 vs fair value $11.80, offering -21% return potential with 68% loss probability amid construction headwinds and competitive pressures.
View noteOrora trades at A$1.89 versus A$2.38 fair value with 26% upside potential. Strong market positions offset by customer concentration risks and integration challenges.
View noteHealthcare IT company trading at $0.24 vs $0.095 fair value. Strong recurring revenue model offset by execution risks and EMR competition. 60% overvalued.
View noteHOLD rating with $0.40 fair value vs $0.37 current price. Strong 20.5% ROIC and underground expansion offset by peak cycle positioning and execution risks.
View noteHOLD rating with $3.98 fair value vs $4.00 current price. Platform transformation showing 26.9% CAGR but facing Amazon competitive threat.
View noteHOLD rating with $4.75 fair value vs $5.27 current price. 98.5% occupancy but office headwinds and 7.2x leverage create challenging outlook.
View noteTrading at $2.94 vs $6.91 fair value (135% upside). Strong balance sheet, 48% recurring revenue, 23.1% ROIC. Cyclical normalisation expected.
View noteCyclopharm trades at $0.99 vs $1.18 fair value with 85% global market share in lung imaging, 29% revenue CAGR projected through US expansion
View noteTrading at NZ$8.78 vs fair value NZ$5.06 (42% overvalued). China concentration (68% revenue) and imminent competitive entry (60% probability within 24 months) threaten premium positioning. EBITDA margins compressing from 15.1% peak to 14.0% as moat narrows.
View noteSELL rating with fair value $2.17 vs current $3.28. Strong platform economics validated but 51% overvaluation unsustainable.
View noteHOLD rating with $4.73 fair value vs $4.25 current price. Regional bank executing Auswide merger targeting $20-25m synergies, 11.3% upside potential.
View note